Esperion Therapeutics Stock Working Capital

ESPR Stock

USD 2.54 0.03 1.17%

Esperion Therapeutics fundamentals help investors to digest information that contributes to Esperion Therapeutics' financial success or failures. It also enables traders to predict the movement of Esperion Stock. The fundamental analysis module provides a way to measure Esperion Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Esperion Therapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	44.8 M	42.6 M
Change In Working Capital	13.7 M	14.4 M

As of 11/28/2024, Change In Working Capital is likely to grow to about 14.4 M, while Net Working Capital is likely to drop slightly above 42.6 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Esperion Therapeutics Company Working Capital Analysis

Esperion Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Esperion Therapeutics Working Capital

44.84 M

Most of Esperion Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Esperion Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Esperion Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Esperion Therapeutics is extremely important. It helps to project a fair market value of Esperion Stock properly, considering its historical fundamentals such as Working Capital. Since Esperion Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Esperion Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Esperion Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Intangible Assets	Short Term Investments	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		-0.43	-0.01	-0.52	0.48	0.49	0.98	0.03	0.39	-0.4	0.43	0.49	0.59	0.09	-0.2	0.71	0.48	0.56	0.54	-0.32	0.29	0.24	0.21
Total Stockholder Equity	-0.43		-0.22	0.75	-0.65	-0.76	-0.58	-0.41	-0.48	0.16	0.32	-0.86	-0.15	-0.26	0.81	-0.74	0.2	-0.72	-0.82	0.69	-0.05	-0.49	-0.47
Net Debt	-0.01	-0.22		-0.71	0.24	0.72	0.02	0.92	0.88	-0.06	-0.31	0.64	-0.56	0.94	-0.7	0.46	0.06	0.44	0.49	-0.76	-0.69	0.83	0.89
Retained Earnings	-0.52	0.75	-0.71		-0.7	-0.96	-0.62	-0.76	-0.92	0.28	0.2	-0.97	0.03	-0.77	0.88	-0.91	-0.08	-0.87	-0.92	0.96	0.39	-0.82	-0.85
Accounts Payable	0.48	-0.65	0.24	-0.7		0.61	0.6	0.29	0.49	-0.26	-0.09	0.7	0.35	0.4	-0.52	0.71	-0.29	0.87	0.84	-0.69	-0.26	0.31	0.34
Total Liab	0.49	-0.76	0.72	-0.96	0.61		0.59	0.8	0.89	-0.22	-0.35	0.97	-0.05	0.76	-0.93	0.82	0.03	0.77	0.85	-0.91	-0.24	0.81	0.84
Total Current Assets	0.98	-0.58	0.02	-0.62	0.6	0.59		0.1	0.43	-0.4	0.32	0.6	0.6	0.14	-0.34	0.79	0.32	0.64	0.66	-0.44	0.25	0.31	0.28
Short Term Debt	0.03	-0.41	0.92	-0.76	0.29	0.8	0.1		0.83	-0.21	-0.44	0.72	-0.47	0.86	-0.82	0.51	-0.01	0.48	0.56	-0.79	-0.52	0.82	0.88
Common Stock	0.39	-0.48	0.88	-0.92	0.49	0.89	0.43	0.83		-0.25	-0.18	0.85	-0.23	0.91	-0.79	0.76	0.19	0.71	0.76	-0.92	-0.58	0.87	0.92
Intangible Assets	-0.4	0.16	-0.06	0.28	-0.26	-0.22	-0.4	-0.21	-0.25		-0.2	-0.23	-0.18	-0.11	0.09	-0.33	-0.18	-0.28	-0.28	0.22	0.07	-0.14	-0.15
Short Term Investments	0.43	0.32	-0.31	0.2	-0.09	-0.35	0.32	-0.44	-0.18	-0.2		-0.32	0.24	-0.35	0.59	0.07	0.55	-0.05	-0.17	0.33	0.08	-0.27	-0.29
Long Term Debt	0.49	-0.86	0.64	-0.97	0.7	0.97	0.6	0.72	0.85	-0.23	-0.32		0.01	0.7	-0.92	0.86	-0.05	0.84	0.94	-0.93	-0.29	0.76	0.78
Property Plant Equipment	0.59	-0.15	-0.56	0.03	0.35	-0.05	0.6	-0.47	-0.23	-0.18	0.24	0.01		-0.33	0.24	0.17	0.05	0.15	0.21	0.09	0.45	-0.36	-0.39
Current Deferred Revenue	0.09	-0.26	0.94	-0.77	0.4	0.76	0.14	0.86	0.91	-0.11	-0.35	0.7	-0.33		-0.7	0.53	0.01	0.56	0.63	-0.84	-0.7	0.79	0.85
Net Tangible Assets	-0.2	0.81	-0.7	0.88	-0.52	-0.93	-0.34	-0.82	-0.79	0.09	0.59	-0.92	0.24	-0.7		-0.69	0.2	-0.66	-0.77	0.87	0.27	-0.8	-0.82
Capital Surpluse	0.71	-0.74	0.46	-0.91	0.71	0.82	0.79	0.51	0.76	-0.33	0.07	0.86	0.17	0.53	-0.69		0.22	0.87	0.86	-0.81	-0.22	0.75	0.73
Long Term Investments	0.48	0.2	0.06	-0.08	-0.29	0.03	0.32	-0.01	0.19	-0.18	0.55	-0.05	0.05	0.01	0.2	0.22		0.05	-0.11	0.05	0.07	0.17	0.15
Long Term Debt Total	0.56	-0.72	0.44	-0.87	0.87	0.77	0.64	0.48	0.71	-0.28	-0.05	0.84	0.15	0.56	-0.66	0.87	0.05		0.88	-0.82	-0.31	0.55	0.57
Short Long Term Debt	0.54	-0.82	0.49	-0.92	0.84	0.85	0.66	0.56	0.76	-0.28	-0.17	0.94	0.21	0.63	-0.77	0.86	-0.11	0.88		-0.91	-0.35	0.62	0.64
Net Invested Capital	-0.32	0.69	-0.76	0.96	-0.69	-0.91	-0.44	-0.79	-0.92	0.22	0.33	-0.93	0.09	-0.84	0.87	-0.81	0.05	-0.82	-0.91		0.57	-0.81	-0.86
Net Working Capital	0.29	-0.05	-0.69	0.39	-0.26	-0.24	0.25	-0.52	-0.58	0.07	0.08	-0.29	0.45	-0.7	0.27	-0.22	0.07	-0.31	-0.35	0.57		-0.47	-0.55
Capital Stock	0.24	-0.49	0.83	-0.82	0.31	0.81	0.31	0.82	0.87	-0.14	-0.27	0.76	-0.36	0.79	-0.8	0.75	0.17	0.55	0.62	-0.81	-0.47		0.99
Net Receivables	0.21	-0.47	0.89	-0.85	0.34	0.84	0.28	0.88	0.92	-0.15	-0.29	0.78	-0.39	0.85	-0.82	0.73	0.15	0.57	0.64	-0.86	-0.55	0.99

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Esperion Therapeutics

Working Capital Over Time

Esperion Capital Surpluse

Capital Surpluse

676.26 Million

At this time, Esperion Therapeutics' Capital Surpluse is relatively stable compared to the past year.

According to the company's disclosures, Esperion Therapeutics has a Working Capital of 44.84 M. This is 89.47% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 96.97% higher than that of the company.

Esperion Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Esperion Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics of similar companies.

Esperion Therapeutics is currently under evaluation in working capital category among its peers.

Esperion Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Esperion Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Esperion Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Esperion Fundamentals

	Return On Equity	-2.61
	Return On Asset	0.0384
	Profit Margin	(0.29) %
	Operating Margin	(0.31) %
	Current Valuation	630.63 M
	Shares Outstanding	197.04 M
	Shares Owned By Insiders	0.49 %
	Shares Owned By Institutions	66.33 %
	Number Of Shares Shorted	31.25 M
	Price To Earning	(8.19) X
	Price To Book	98.42 X
	Price To Sales	1.69 X
	Revenue	116.33 M
	Gross Profit	(70.42 M)
	EBITDA	(150.11 M)
	Net Income	(209.25 M)
	Cash And Equivalents	185.84 M
	Cash Per Share	2.79 X
	Total Debt	540.95 M
	Current Ratio	3.07 X
	Book Value Per Share	(1.89) X
	Cash Flow From Operations	(135.49 M)
	Short Ratio	6.99 X
	Earnings Per Share	(0.67) X
	Price To Earnings To Growth	(4.78) X
	Target Price	7.51
	Number Of Employees	240
	Beta	0.95
	Market Capitalization	500.47 M
	Total Asset	205.8 M
	Retained Earnings	(1.55 B)
	Working Capital	44.84 M
	Current Asset	214.39 M
	Current Liabilities	5.62 M
	Net Asset	205.8 M

About Esperion Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Esperion Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Esperion Stock

0.9

BMY

Bristol Myers Squibb Aggressive Push

Pair Corr

Moving against Esperion Stock

0.84	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.82	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.77	PEPG	PepGen	Pair Corr
0.72	FDMT	4D Molecular Therapeutics	Pair Corr
0.72	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC